Ophthalmology - Vascular Endothelial Growth Factor Inhibitors - Susvimo
Defines Cigna's coverage position for Susvimo (ranibizumab intravitreal injection via ocular implant) across indications (DME, diabetic retinopathy, neovascular AMD), summarizes safety concerns, and provides coding guidance (HCPCS J2779). Applies to health benefit plans administered by Cigna Companies unless superseded by specific plan language or mandates.
Annual Revision dated 3/1/2026 with no criteria changes.
HCPCS coding J2779 added to coding information (2/15/2025).
Diabetic Macular Edema was added to considered experimental/investigational/unproven (6/15/2025).
Diabetic Retinopathy added to Conditions Not Recommended for Approval (8/15/2025).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.